Riboflavin and Its Derivates as Potential Photosensitizers in the Photodynamic Treatment of Skin Cancers

Cells. 2023 Sep 19;12(18):2304. doi: 10.3390/cells12182304.

Abstract

Riboflavin, a water-soluble vitamin B2, possesses unique biological and physicochemical properties. Its photosensitizing properties make it suitable for various biological applications, such as pathogen inactivation and photodynamic therapy. However, the effectiveness of riboflavin as a photosensitizer is hindered by its degradation upon exposure to light. The review aims to highlight the significance of riboflavin and its derivatives as potential photosensitizers for use in photodynamic therapy. Additionally, a concise overview of photodynamic therapy and utilization of blue light in dermatology is provided, as well as the photochemistry and photobiophysics of riboflavin and its derivatives. Particular emphasis is given to the latest findings on the use of acetylated 3-methyltetraacetyl-riboflavin derivative (3MeTARF) in photodynamic therapy.

Keywords: 3MeTARF; PDT; lumichrome; melanoma; riboflavin; singlet oxygen; skin cancer.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Photochemotherapy*
  • Photosensitizing Agents / pharmacology
  • Photosensitizing Agents / therapeutic use
  • Riboflavin / pharmacology
  • Skin Neoplasms* / drug therapy
  • Vitamins

Substances

  • Photosensitizing Agents
  • Riboflavin
  • Vitamins

Grants and funding

This research was funded in part by the National Science Centre, Poland, grant number 2017/27/B/ST4/02494 to MS.